India Pharma Could Mirror IT's 20-Year Wealth-Creation Run, Says Bandyopadhyay

Analyst flags China+1 tailwinds, rising domestic demand and CDMO growth as converging catalysts, favouring branded makers, contract manufacturers and hospital chains.

bt-corporate · 6/30/2026, 10:03:03 AM · Ask about this →